Research Study

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Hepatitis C
ClinicalTrials.gov# 
NCT02446717
Status 
Closed to Recruitment
Study Start/End 
Feb 1, 2016 to Oct 31, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann E. Ford, Adjunct Professor
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.